Precision hopes to cure chronic hepatitis B with gene editing
Precision BioSciences has announced it will commence a Phase I clinical trial for its in vivo gene editing programme PBGENE-HBV, following Clinical Trial Application (CTA) approval in Moldova.
PBGENE-HBV is designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus (HBV), while also inactivating integrated HBV DNA in hepatocytes.
The current standard of care requires daily chronic treatment with nucleos(t)ide analogues and only offers patients a 1-3% chance of functional cure.
“With rapid regulatory approval in hand, we are working diligently to screen and dose patients at our first clinical site in Moldova,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “In parallel, we are leveraging our robust regulatory package, which highlights the safety and potent antiviral effects of PBGENE-HBV in a variety of models, including non-human primates, to pursue additional CTA and IND approvals globally. This multi-track approach will enable us to accelerate enrolment into the trial and generate important clinical safety and efficacy data with the aim of bringing a potentially curative treatment to the nearly 300 million patients living with chronic hepatitis B globally.”
Gene editing platform
PBGENE-HBV is engineered to target the HBV viral genome and drive functional cures for patients with chronic hepatitis B. It leverages the ARCUS gene editing platform by delivering an ARCUS nuclease-encoding mRNA to the liver via lipid nanoparticles.
When expressed in HBV-infected hepatocytes, the ARCUS nuclease specifically cuts a highly conserved sequence in the hepatitis B viral genome and is designed to eliminate cccDNA and inactivate integrated HBV genomes.
“We are thrilled to receive CTA approval in Moldova given the high prevalence of chronic hepatitis B in the country and their expertise gained from multiple Phase I clinical trials in hepatitis B. Our clinical team, guided by our hepatitis scientific advisory board, has deep expertise in hepatitis B, and we believe that we are well-positioned to advance PBGENE-HBV towards dosing the first patient in the clinic,” added Dr Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences.
Diana Spencer, Senior Digital Content Editor, DDW
